Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Conditions
- Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT04685135
- Lead Sponsor
- Mirati Therapeutics Inc.
- Brief Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 453
- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
Crossover Inclusion Criteria:
- Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- ECOG performance status 0-2
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
- Active brain metastases.
Crossover Exclusion Criteria:
- Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MRTX849 MRTX849 - Docetaxel Docetaxel -
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) as Per Blinded Independent Central Review From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks) Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) From randomization till death due to any cause (up to approximately 143 weeks) Overall survival is defined as the time from randomization to the date of death due to any cause.
Objective Response Rate (ORR) as Per Blinded Independent Central Review From randomization till death or till disease progression or initiation of follow-up anti-cancer therapy or withdrawal of consent prior to minimum efficacy follow-up (up to 143 weeks) Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
Duration of Response (DOR) as Per Blinded Independent Central Review First documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause (Up to approximately 22 months) Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
1-Year Survival Rate Up to 49 months Number of Participants With Treatment Emergent Adverse Events (TEAEs) From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks) Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks) Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks) Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Plasma Concentration of Adagrasib Day 1 of Cycle 1 (Pre-Dose and Peak), Cycle 2 (Pre-Dose and Peak), Cycle 3 (Pre-Dose), Cycle 5 (Pre-Dose), Cycle 7 (Pre-Dose) (Each cycle is of 21 days) Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks) The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Least Square Mean and Confidence Interval are from a repeated measures model on the response variable change from baseline in LCSS average total score.
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks) The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.
Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks) The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average 3-item global index score assesses the following 3 items (Distress/severity of symptoms from lung cancer, impact on normal activities, quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The 3 item global index score is average of all the 3 items ranging from 0 to 100 where high score represent worst outcome. LS mean and CI are from a repeated measures model on the response variable change from baseline in 3-item global index score.
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks) The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks) The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.
Trial Locations
- Locations (343)
Local Institution - 012-898
🇺🇸Cerritos, California, United States
Local Institution - 012-898 D
🇺🇸Glendale, California, United States
Local Institution - 012-910-A
🇺🇸Huntington Beach, California, United States
Local Institution - 012-910-C
🇺🇸Irvine, California, United States
City Of Hope
🇺🇸Long Beach, California, United States
Local Institution - 012-910-F
🇺🇸Long Beach, California, United States
Local Institution - 012-910-D
🇺🇸Newport Beach, California, United States
Local Institution - 012-898 C
🇺🇸Santa Ana, California, United States
Local Institution - 012-910-E
🇺🇸Torrance, California, United States
Local Institution - 012-951-B
🇺🇸Denver, Colorado, United States
Local Institution - 012-872
🇺🇸Lone Tree, Colorado, United States
Local Institution - 012-951-A
🇺🇸Wheat Ridge, Colorado, United States
Local Institution - 012-562-B
🇺🇸Fleming Island, Florida, United States
Local Institution - 012-562-D
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562-E
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562-A
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562-C
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562-F
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562-G
🇺🇸Jacksonville, Florida, United States
Local Institution - 012-562
🇺🇸Jacksonville, Florida, United States
Mount Sinai Comprehensive Cancer Center
🇺🇸Miami Beach, Florida, United States
Local Institution - 012-839
🇺🇸Plantation, Florida, United States
Local Institution - 012-835 - A
🇺🇸Austell, Georgia, United States
Local Institution - 012-835 - B
🇺🇸Carrollton, Georgia, United States
Local Institution - 012-835 - C
🇺🇸Cartersville, Georgia, United States
Local Institution - 012-835 - D
🇺🇸Douglasville, Georgia, United States
Local Institution - 012-972 C
🇺🇸Harvey, Illinois, United States
Local Institution - 012-972 A
🇺🇸New Lenox, Illinois, United States
Local Institution - 012-972 B
🇺🇸Orland Park, Illinois, United States
Local Institution - 012-569
🇺🇸Indianapolis, Indiana, United States
Local Institution - 012-569 - B
🇺🇸Lafayette, Indiana, United States
Local Institution - 012-569 - C
🇺🇸Lafayette, Indiana, United States
Local Institution - 012-569 - A
🇺🇸Mooresville, Indiana, United States
Local Institution - 012-942-B
🇺🇸Chanute, Kansas, United States
Local Institution - 012-942-C
🇺🇸Dodge City, Kansas, United States
Local Institution - 012-942-D
🇺🇸El Dorado, Kansas, United States
Local Institution - 012-942-E
🇺🇸Independence, Kansas, United States
Local Institution - 012-942-F
🇺🇸Kingman, Kansas, United States
Local Institution - 012-942-G
🇺🇸Liberal, Kansas, United States
Local Institution - 012-942-H
🇺🇸McPherson, Kansas, United States
Local Institution - 012-942-I
🇺🇸Newton, Kansas, United States
Local Institution - 012-942-J
🇺🇸Parsons, Kansas, United States
Local Institution - 012-942-K
🇺🇸Pratt, Kansas, United States
Local Institution - 012-942-L
🇺🇸Salina, Kansas, United States
Local Institution - 012-942-M
🇺🇸Wellington, Kansas, United States
Local Institution - 012-820
🇺🇸Westwood, Kansas, United States
Local Institution - 012-942-A
🇺🇸Wichita, Kansas, United States
Local Institution - 012-942
🇺🇸Wichita, Kansas, United States
Local Institution - 012-942-N
🇺🇸Winfield, Kansas, United States
Local Institution - 012-911 A
🇺🇸New Orleans, Louisiana, United States
Local Institution - 012-954 - A
🇺🇸Kennebunk, Maine, United States
Local Institution - 012-954 - B
🇺🇸Topsham, Maine, United States
Local Institution - 012-974-B
🇺🇸Novi, Michigan, United States
Local Institution - 012-974-C
🇺🇸Novi, Michigan, United States
Local Institution - 012-974-A
🇺🇸Southfield, Michigan, United States
Local Institution - 012-841 - A
🇺🇸Billings, Montana, United States
Local Institution - 012-975 - A
🇺🇸Edison, New Jersey, United States
Local Institution - 012-975 - B
🇺🇸Monroe, New Jersey, United States
Local Institution - 012-975 - C
🇺🇸Somerset, New Jersey, United States
Local Institution - 012-975 - D
🇺🇸Somerville, New Jersey, United States
Local Institution - 012-960-A
🇺🇸Providence, Rhode Island, United States
Texas Oncology - Dallas Fort Worth (DFW) - Arlington Cancer Center North
🇺🇸Arlington, Texas, United States
Texas Oncology - Dallas Fort Worth (DFW) - South Austin
🇺🇸Austin, Texas, United States
US Oncology Research (USOR)
🇺🇸Irving, Texas, United States
Local Institution - 012-976-A
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-B
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-C
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-D
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-E
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-F
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-G
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-H
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-976-I
🇺🇸Salt Lake City, Utah, United States
Local Institution - 012-814 - B
🇺🇸Arlington, Virginia, United States
Local Institution - 012-814 - A
🇺🇸Fairfax, Virginia, United States
Local Institution - 012-814 - C
🇺🇸Gainesville, Virginia, United States
Local Institution - 012-814 - D
🇺🇸Leesburg, Virginia, United States
Local Institution - 012-016
🇦🇺Mackay, Queensland, Australia
Local Institution - 012-005
🇦🇺Bedford Park, Australia
Local Institution - 012-004
🇦🇺Clayton, Australia
Local Institution - 012-013
🇦🇺St. Leonards, Australia
Local Institution - 012-019
🇦🇺Tweed Heads, Australia
Local Institution - 012-157
🇧🇪Edegem, Belgium
Local Institution - 012-155
🇧🇪Gent, Belgium
Local Institution - 012-151
🇧🇪Gilly, Belgium
Local Institution - 012-158
🇧🇪Hasselt, Belgium
Local Institution - 012-152
🇧🇪Roeselare, Belgium
Local Institution - 012-150
🇧🇪Yvoir, Belgium
Local Institution - 012-164
🇨🇿Horovice, Czechia
Local Institution - 012-162
🇨🇿Olomouc, Czechia
Vseobecna Fakultni Nemocnice v Praze
🇨🇿Praha 2, Czechia
Local Institution - 012-191-A
🇫🇷Pierre Benite, Rhone-Alpes, France
Local Institution - 012-191-B
🇫🇷Lyon, Rhone, France
Local Institution - 012-194
🇫🇷Brest, France
Local Institution - 012-193
🇫🇷Caen Cedex 09, France
Local Institution - 012-196
🇫🇷Caen Cedex 5, France
Local Institution - 012-192
🇫🇷Dijon cedex, France
Local Institution - 012-685
🇫🇷Nice Cedex 2, France
Local Institution - 012-197
🇫🇷Strasbourg, France
Local Institution - 012-219
🇩🇪Bad Berka, Germany
Local Institution - 012-210
🇩🇪Essen, Germany
Local Institution - 012-214
🇩🇪Gauting, Germany
Local Institution - 012-671
🇩🇪Giessen, Germany
Local Institution - 012-215
🇩🇪Halle, Germany
Local Institution - 012-224
🇩🇪Lowenstein, Germany
Local Institution - 012-216
🇩🇪Lubeck, Germany
Local Institution - 012-220
🇩🇪Munchen, Germany
Local Institution - 012-672
🇩🇪Offenbach, Germany
Local Institution - 012-236
🇬🇷Athens, Greece
Local Institution - 012-235
🇬🇷Larissa, Greece
Local Institution - 012-234
🇬🇷Peiraias, Greece
Local Institution - 012-230
🇬🇷Thessaloniki, Greece
Local Institution - 012-500
🇬🇷Thessaloniki, Greece
Local Institution - 012-242
🇭🇺Budapest, Hungary
Local Institution - 012-244
🇭🇺Budapest, Hungary
Local Institution - 012-241
🇭🇺Budapest, Hungary
Local Institution - 012-243
🇭🇺Gyongyos, Hungary
Local Institution - 012-763
🇭🇺Gyula, Hungary
Local Institution - 012-759
🇭🇺Szekesfehervar, Hungary
Local Institution - 012-276
🇮🇹Alessandria, Italy
Local Institution - 012-292
🇮🇹Avellino, Italy
Local Institution - 012-274
🇮🇹Aviano, Italy
Local Institution - 012-275
🇮🇹Bari, Italy
Local Institution - 012-765
🇮🇹Brescia, Italy
Local Institution - 012-286
🇮🇹Candiolo, Italy
Local Institution - 012-284
🇮🇹Catania, Italy
Local Institution - 012-282
🇮🇹Catania, Italy
Local Institution - 012-762
🇮🇹Firenze, Italy
Local Institution - 012-273
🇮🇹Genova, Italy
Local Institution - 012-285
🇮🇹Genova, Italy
Local Institution - 012-279
🇮🇹Lecce, Italy
Local Institution - 012-283
🇮🇹Milano, Italy
Local Institution - 012-296
🇮🇹Milan, Italy
Local Institution - 012-278
🇮🇹Milan, Italy
Local Institution - 012-271
🇮🇹Napoli, Italy
Local Institution - 012-277
🇮🇹Napoli, Italy
Local Institution - 012-770
🇮🇹Novara, Italy
Local Institution - 012-272
🇮🇹Parma, Italy
Local Institution - 012-281
🇮🇹Perugia, Italy
Local Institution - 012-766
🇮🇹Pesaro, Italy
Local Institution - 012-767
🇮🇹Ravenna, Italy
Local Institution - 012-295
🇮🇹Roma, Italy
Local Institution - 012-758
🇮🇹Verona, Italy
Local Institution - 012-522
🇰🇷Busan-si, Korea, Republic of
Local Institution - 012-111
🇰🇷Busan, Korea, Republic of
Local Institution - 012-101
🇰🇷Busan, Korea, Republic of
Local Institution - 012-110
🇰🇷Daegu, Korea, Republic of
Local Institution - 012-523
🇰🇷Daegu, Korea, Republic of
Local Institution - 012-100
🇰🇷Hwasun-gun, Korea, Republic of
Local Institution - 012-103
🇰🇷Incheon, Korea, Republic of
Local Institution - 012-102
🇰🇷Jung-Gu, Korea, Republic of
Local Institution - 012-520
🇰🇷Seongnam-si, Korea, Republic of
Local Institution - 012-112
🇰🇷Seongnam-si, Korea, Republic of
Local Institution - 012-118
🇰🇷Seoul, Korea, Republic of
Local Institution - 012-106
🇰🇷Seoul, Korea, Republic of
Catholic University of Korea St. Vincents Hospital
🇰🇷Suwon-Si, Korea, Republic of
Local Institution - 012-107
🇰🇷Suwon-si, Korea, Republic of
Local Institution - 012-306
🇳🇱Amsterdam, Netherlands
Amphia Ziekenhuis - Breda Molengracht
🇳🇱Breda, Netherlands
Local Institution - 012-308
🇳🇱Den Haag, Netherlands
Local Institution - 012-300
🇳🇱Maastricht, Netherlands
Local Institution - 012-630
🇳🇱Nijmegen, Netherlands
Local Institution - 012-307
🇳🇱Utrecht, Netherlands
Local Institution - 012-321
🇵🇱Lublin, Poland
Local Institution - 012-760
🇵🇱Lublin, Poland
Local Institution - 012-325
🇵🇱Otwock, Poland
Local Institution - 012-320
🇵🇱Rzeszow, Poland
Local Institution - 012-324
🇵🇱Skorzewo, Poland
Local Institution - 012-322
🇵🇱Warszawa, Poland
Local Institution - 012-330
🇵🇹Coimbra, Portugal
Local Institution - 012-645
🇵🇹Coimbra, Portugal
Local Institution - 012-333
🇵🇹Guimaraes, Portugal
Local Institution - 012-338-A
🇵🇹Lisboa, Portugal
Local Institution - 012-642
🇵🇹Lisbon, Portugal
Local Institution - 012-338
🇵🇹Lisbon, Portugal
Local Institution - 012-331
🇵🇹Porto, Portugal
Local Institution - 012-339
🇵🇹Porto, Portugal
FDI Clinical Research (Fundacion de Investigacion de Diego) - San Juan
🇵🇷San Juan, Puerto Rico
Local Institution - 012-342
🇷🇴Bucharest, Romania
Local Institution - 012-344
🇷🇴Cluj-Napoca, Romania
Local Institution - 012-340
🇷🇴Cluj-Napoca, Romania
Local Institution - 012-343
🇷🇴Craiova, Romania
Local Institution - 012-513
🇷🇴Iasi, Romania
Local Institution - 012-355
🇷🇺Saint Petersburg, Russian Federation
Local Institution - 012-354
🇷🇺Saint Petersburg, Russian Federation
Local Institution - 012-093
🇸🇬Singapore, Singapore
Clinica Universidad de Navarra - Pamplona
🇪🇸Pamplona, Navarre, Spain
Local Institution - 012-613
🇪🇸A Coruna, Spain
Local Institution - 012-769
🇪🇸Alicante, Spain
Local Institution - 012-776
🇪🇸Barakaldo, Spain
Local Institution - 012-614
🇪🇸Barcelona, Spain
Local Institution - 012-612
🇪🇸Barcelona, Spain
Local Institution - 012-600
🇪🇸Barcelona, Spain
Local Institution - 012-621
🇪🇸Cordoba, Spain
Local Institution - 012-764
🇪🇸Girona, Spain
Local Institution - 012-616
🇪🇸Granada, Spain
Local Institution - 012-615
🇪🇸Lugo, Spain
Local Institution - 012-607
🇪🇸Madrid, Spain
Local Institution - 012-606
🇪🇸Madrid, Spain
Local Institution - 012-601
🇪🇸Madrid, Spain
Local Institution - 012-609
🇪🇸Madrid, Spain
Local Institution - 012-626
🇪🇸Majadahonda, Spain
Local Institution - 012-608
🇪🇸Malaga, Spain
Local Institution - 012-602
🇪🇸Palma de Mallorca, Spain
Local Institution - 012-604
🇪🇸Santander, Spain
Local Institution - 012-629
🇪🇸Sevilla, Spain
Local Institution - 012-603
🇪🇸Zaragoza, Spain
Spital Simmental-Thun-Saanenland
🇨🇭Thun, Switzerland
University Hospitals Birmingham NHS Foundation Trust
🇬🇧Birmingham, United Kingdom
City of Hope - Duarte (Main Campus)
🇺🇸Duarte, California, United States
Providence Medical Group - Santa Rosa
🇺🇸Santa Rosa, California, United States
SCL Health - Saint Joseph Hospital Cancer Center
🇺🇸Lafayette, Colorado, United States
Holy Cross Health Fort Lauderdale - Holy Cross Hospital
🇺🇸Fort Lauderdale, Florida, United States
21st Century Oncology of Jacksonville - North Lee Street
🇺🇸Jacksonville, Florida, United States
Orlando Health University of Florida Health Cancer Center - Head and Neck Center
🇺🇸Orlando, Florida, United States
USOR - Woodlands Medical Specialists
🇺🇸Pensacola, Florida, United States
University Cancer & Blood Center (UCBC) - Athens
🇺🇸Athens, Georgia, United States
Northwest Georgia Oncology Centers Wellstar - Marietta
🇺🇸Marietta, Georgia, United States
University of Illinois Hospital & Health Sciences System
🇺🇸Chicago, Illinois, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
Illinois Cancer Specialists - Niles
🇺🇸Niles, Illinois, United States
Goshen Center for Cancer Care
🇺🇸Goshen, Indiana, United States
Franciscan Health Munster
🇺🇸Munster, Indiana, United States
Baptist Health Lexington
🇺🇸Lexington, Kentucky, United States
Tulane University
🇺🇸New Orleans, Louisiana, United States
New England Cancer Specialists - Scarborough
🇺🇸Scarborough, Maine, United States
Frederick Health
🇺🇸Frederick, Maryland, United States
Ascension Providence Cancer Center - Southfield
🇺🇸Southfield, Michigan, United States
Central Care Cancer Center - Bolivar
🇺🇸Bolivar, Missouri, United States
St. Vincent Healthcare Cancer Centers of Montana
🇺🇸Billings, Montana, United States
Sisters of Charity of Leavenworth Health St. Marys
🇺🇸Billings, Montana, United States
Astera Cancer Care - East Brunswick
🇺🇸East Brunswick, New Jersey, United States
Holy Name Medical Center
🇺🇸Teaneck, New Jersey, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Kettering Health Cancer Center - Main Campus
🇺🇸Kettering, Ohio, United States
Oregon Oncology Specialists
🇺🇸Salem, Oregon, United States
Lifespan Cancer Institute - Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Prisma Health Cancer Institute - Faris Road
🇺🇸Greenville, South Carolina, United States
Avera Cancer Institute
🇺🇸Sioux Falls, South Dakota, United States
Texas Oncology - Sherman
🇺🇸Sherman, Texas, United States
Utah Cancer Specialists - UCS Cancer Center
🇺🇸Salt Lake City, Utah, United States
UVA Health - University Hospital
🇺🇸Charlottesville, Virginia, United States
NEXT Virginia
🇺🇸Fairfax, Virginia, United States
Townsville University Hospital
🇦🇺Douglas, Australia
Cancer Care Wollongong
🇦🇺Wollongong, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Klinikum Klagenfurt Am Worthersee
🇦🇹Klagenfurt Am Woerthersee, Austria
Uniklinikum Salzburg
🇦🇹Salzburg, Austria
Wiener Gesundheitsverbund - Klinik Ottakring
🇦🇹Wien, Austria
Universitair Ziekenhuis Brussel
🇧🇪Brussel, Belgium
Algemeen Ziekenhuis Glorieux Ronse
🇧🇪Ronse, Belgium
Fakultni nemocnice Bulovka
🇨🇿Praha 8 - Liben, Czechia
Hopital Louis Pradel
🇫🇷Bron, France
Centre Hospitalier Intercommunal de Creteil
🇫🇷Creteil, France
LHopital Nord-Ouest (HNO) - Villefranche-sur-Saone
🇫🇷Gleize, France
Hopital Michallon
🇫🇷La Tronche, France
Centre Hospitalier Regional Universitaire de Lille
🇫🇷Lille Cedex, France
Centre Hospitalier Universitaire Dupuytren 1
🇫🇷Limoges cedex, France
Institut Paoli-Calmettes
🇫🇷Marseille, France
Hopital Nord de Marseille
🇫🇷Marseille, France
Hopital Arnaud de Villeneuve
🇫🇷Montpellier, France
Hopital Emile Muller
🇫🇷Mulhouse, France
Centre Hospitalier de Cornouaille - Hopital Laennec
🇫🇷Quimper, France
Institut de Cancerologie de lOuest - Saint-Herblain - Site Rene Gauducheau
🇫🇷Saint Herblain, France
Hopital Civil
🇫🇷Strasbourg cedex, France
Hopital Bretonneau
🇫🇷Tours Cedex 9, France
Gustave Roussy
🇫🇷Villejuif, France
Universitatsklinikum Bonn
🇩🇪Bonn, Germany
LungenClinic Grosshansdorf
🇩🇪Grohansdorf, Germany
Universitatsklinikum Jena
🇩🇪Jena, Germany
Klinikum Kassel
🇩🇪Kassel, Germany
Klinikum Koln-Merheim
🇩🇪Koln, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
Henry Dunant Hospital Center
🇬🇷Athens, Attiki, Greece
University General Hospital of Heraklion (PAGNI)
🇬🇷Heraklion, Greece
"General Oncology Hospital of Kifisias "Agioi Anargyroi""
🇬🇷Nea Kifisia, Greece
Metropolitan Hospital
🇬🇷Peiraias, Greece
BioClinic Thessaloniki
🇬🇷Thessaloniki, Greece
Anassa General Clinic
🇬🇷Volos, Greece
Humanity & Health Clinical Trial Centre
🇭🇰Central, Hong Kong
Prince of Wales Hospital - Hong Kong
🇭🇰Hong Kong, Hong Kong
Hong Kong United Oncology Centre
🇭🇰Kowloon, Hong Kong
Reformatus Pulmonologiai Centrum
🇭🇺Torokbalint, Hungary
The Meath Foundation
🇮🇪Tallaght, Dublin, Ireland
St. Vincents University Hospital
🇮🇪Dublin, Ireland
Beaumont Hospital - Dublin
🇮🇪Dublin, Ireland
St. Jamess Hospital
🇮🇪Dublin, Ireland
University Hospital Galway
🇮🇪Galway, Ireland
University Hospital Limerick
🇮🇪Limerick, Ireland
"Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST"
🇮🇹Meldola, Italy
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea - Seoul St. Marys Hospital
🇰🇷Seoul, Korea, Republic of
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
Instytut MSF
🇵🇱Lodz, Poland
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
🇵🇱Torun, Poland
Wojskowy Instytut Medyczny
🇵🇱Warsaw, Poland
Unidade Local de Saude de Almada-Seixal, E. P. E (Hospital Garcia de Orta)
🇵🇹Almada, Portugal
Unidade Local de Saude de Braga, E. P. E (Hospital de Braga)
🇵🇹Braga, Portugal
The Champalimaud Centre for the Unknown
🇵🇹Lisbon, Portugal
Unidade Local de Saude de Loures-Odivelas, EPE (Hospital Beatriz Angelo)
🇵🇹Loures, Portugal
Hospital CUF Porto
🇵🇹Porto, Portugal
Unidade Local de Saude de Entre Douro e Vouga, E. P. E
🇵🇹Santa Maria Da Feira, Portugal
Unidade Local de Saude da Arrabida, E. P. E (Centro Hospitalar de Setubal)
🇵🇹Setubal, Portugal
Unidade Local de Saude de Gaia/Espinho, E. P. E
🇵🇹Vila Nova de Gaia, Portugal
Puerto Rico Medical Research Center
🇵🇷San Juan, Puerto Rico
PanOncology Trials - Rio Piedras Medical Center
🇵🇷San Juan, Puerto Rico
Spitalul Jude�ean de Urgen�a dr. Constantin Opri� Baia Mare
🇷🇴Baia Mare, Romania
SC Policlinica de Diagnostic Rapid SA
🇷🇴Brașov, Romania
Centrul Oncologic Sanador
🇷🇴București, Romania
Oncolab Craiova
🇷🇴Craiova, Romania
Ovidius Clinical Hospital
🇷🇴Ovidiu, Romania
SC OncoMed SRL
🇷🇴Timisoara, Romania
Oncocenter - Oncologie Clinica
🇷🇴Timișoara, Romania
Evimed Oncology Clinic
🇷🇺Chelyabinsk, Russian Federation
"Budgetary Healthcare Institution of the Udmurt Republic "Republican Clinical Oncological Dispensary n.a. Sergey Grigoryevich Pr
🇷🇺Izhevsk, Russian Federation
"Regional Budgetary Healthcare Institution "G.E. Ostroverkhov Kursk Oncology Scientific and Clinical Center" of the Healthcare C
🇷🇺Kislino Village, Russian Federation
VitaMed - Moscow
🇷🇺Moscow, Russian Federation
University Headache Clinic
🇷🇺Moscow, Russian Federation
State Budgetary Healthcare Institution of the Nizhny Novgorod Region Clinical Diagnostic Center
🇷🇺Nizhniy Novgorod, Russian Federation
"Limited Liability Company Medical Sanitary Unit "Clinicist-Clinic Pretor""
🇷🇺Novosibirsk, Russian Federation
"Budgetary Healthcare Institution of Omsk region "Clinical Oncologic Dispensary""
🇷🇺Omsk, Russian Federation
"Federal State Budgetary Institution "Influenza Research Institute named after N.N. A.A. Smorodintsev" of the Ministry of Health
🇷🇺Saint-Petersburg, Russian Federation
Raffles Hospital
🇸🇬Singapore, Singapore
Icon Cancer Centre Farrer Park
🇸🇬Singapore, Singapore
Oncocare Cancer Centre
🇸🇬Singapore, Singapore
Parkway Cancer Centre - Gleneagles Hospital
🇸🇬Singapore, Singapore
Hospital Germans Trias i Pujol
🇪🇸Badalona, Spain
Hospital del Mar - Parc de Salut Mar
🇪🇸Barcelona, Spain
Complejo Hospitalario Universitario Insular Materno Infantil
🇪🇸Las Palmas de Gran Canaria, Spain
Hospital de Leon
🇪🇸Leon, Spain
Clinica Universidad de Navarra - Madrid
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Consorci Hospital General Universitari de Valencia
🇪🇸Valencia, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Universitatsspital Basel
🇨🇭Basel, Switzerland
Kantonsspital Winterthur
🇨🇭Winterthur, Switzerland
NHS Lothian
🇬🇧Edinburgh, United Kingdom
NHS Greater Glasgow and Clyde
🇬🇧Glasgow, United Kingdom
University Hospitals of Leicester NHS Trust
🇬🇧Leicester, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom